[frame src=”https://www.drmcdougall.com/wp/wp-content/uploads/bypass.jpg” width=”IMAGE_WIDTH” height=”IMAGE_HEIGHT” lightbox=”off” title=”High Blood Pressure (Hypertension)” align=”left” ]
Blood pressure rises naturally in response to a clogging of your blood vessels in order to deliver oxygen and nutrients to your body. The pharmaceutical industry’s answer is to inhibit the natural mechanisms of the body, causing the pressure to fall. The problem with this artificial reduction of pressure is that nothing helpful has been accomplished by the medication to improve the health of the blood vessels themselves. The arteries remain fragile and ready to burst into a stroke or heart attack. Attacking the cause of the problem – the rich Western diet – cleans up and strengthens the blood vessels and reduces the resistance to blood flow. Your blood pressure will then fall naturally. In less than 2 weeks of following the McDougall Program, people with high blood pressure (150/90 mmHg or greater) experience an average reduction of 23/14 mmHg and in most cases significantly reduce or stop all blood pressure medications.
(articles open in a new window)
Alderman M. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA. 1989; 262:920. http://jama.jamanetwork.com/article.aspx?articleid=378366
Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009 Jul 8; (3):CD004349. http://www.update-software.com/BCP/WileyPDF/EN/CD004349.pdf
Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer. 2003 Jan; 39(1):98-105. http://igitur-archive.library.uu.nl/phar/2008-0509-201450/beiderbeck_03_verapamilisassociated.pdf
Cruickshank J. Benefits and potential harm of lowering blood pressure. Lancet. 1987;1:581-4. http://www.sciencedirect.com/science/article/pii/S0140673687902315
Diao D, Wright JM, Cundiff DK, Gueyffier F. Benefits of antihypertensive drugs for mild hypertension are unclear. Cochrane Database of Systematic Reviews. 2012; 8. Art. No: CD006742. http://bit.ly/SnZXHJ
Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997 Oct 15; 80(8):1438-47. http://bit.ly/16HgRcH
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351:1755-62. http://www.sciencedirect.com/science/article/pii/S0140673698043116
Houston MC, Basile J, Bestermann WH, Egan B, Lackland D, Hawkins RG, Moore MA, Reed J, Rogers P, Wise D, Ferrario CM. Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci. 2005 Jun;329(6):276-91. http://bit.ly/17Ked4J
Lindberg G, Bingefors K, Ranstam J, Rastam L, Melander A. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. BMJ. 1998 Mar 7; 316(7133):741-5. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC28478/
Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006 Jun 20; 144(12):884-93. http://ww.columbiaresidents.org/bb/AnnInternMed.pdf
Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996 Aug 24; 348(9026):493-7. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)04277-8/abstract
Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995 Aug 23-30; 274(8):620-5. http://jama.jamanetwork.com/article.aspx?articleid=389492
Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction – and patients may need to be told. BMJ. 2004 Nov 27; 329:1248-9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC534428/
Williams B, Poulter NR, Brown MJ, et al; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004 Mar 13; 328(7440):634-40. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC381142/?tool=pubmed